Melanotan 1 vs 2: what each one does
Reviewed 22 sourcesPublished by PepVault
Melanotan 1 is afamelanotide, approved as Scenesse for EPP; melanotan 2 is unapproved. What each does, what trials measured, and how moles change.

- Last reviewed
- Sources
- 22
- Questions
- 9
- Compounds
- 3
The short answer
Both darken skin by copying the body's own tanning hormone. Melanotan 1 is afamelanotide, a 13-amino-acid peptide that works mainly on the pigment receptor and is approved as Scenesse, a 16 mg implant for the light disorder EPP. Melanotan 2 is a smaller, ring-shaped cousin with a broader reach, so its trials also brought erections, yawning and nausea. It has no FDA approval for any use.
Evidence: Melanotan 1: human tanning trials and two phase 3 trials behind an approved EPP implant. Melanotan 2: a three-person tanning pilot, two small erectile-dysfunction trials and case reports.
What is the difference between melanotan 1 and melanotan 2?
Both were taken into people by the same University of Arizona group, chasing one idea: a tan without the sun25. The starting point was α-MSH, the body's own melanocyte-stimulating hormone, a chain of 13 amino acids310.
In 1980, a team that included two of the same researchers swapped two of those 13 amino acids. The result, [Nle4, D-Phe7]-α-MSH, resisted the enzymes in blood serum and was 26 times as potent as α-MSH in a mouse melanoma cell assay1. That molecule is melanotan 1, today called afamelanotide. Melanotan 2 went further: it keeps only the seven positions from the middle of the hormone, 4 to 10, swaps two more of them, and closes them into a ring with a bond between two side chains510. Its own developers describe it as a non-selective melanocortin receptor agonist7.
The two then took different roads. Melanotan 1, the linear one, was tested in people for tanning; melanotan 2, the cyclic one, for erectile dysfunction8.
| Side by side | Melanotan 1 (MT-1) | Melanotan 2 (MT-2) |
|---|---|---|
| Other names | Afamelanotide, Scenesse | MT-II |
| Shape | Linear, 13 amino acids110 | A ring, 7 amino acids5 |
| Main target | The pigment receptor, MC1R10 | Melanocortin receptors broadly7 |
| Tested in people for | Tanning, then EPP29 | Tanning (one pilot), then erectile dysfunction56 |
| Approved | Yes: EU 2014, US 2019, for EPP1112 | No; FDA lists it as a compounding safety risk14 |

How does melanotan tan the skin?
α-MSH darkens skin by binding MC1R, a receptor on the pigment cells, which then make more of the dark pigment eumelanin. The melanotans bind the same receptor themselves, so the sun is no longer needed to start the process. The Scenesse label says it plainly: afamelanotide binds mainly MC1R and raises eumelanin in the skin independently of sunlight or UV lamps10.
Peptide SkySee Melanotan II as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide SkyPicture α-MSH as a string of 13 beads. Melanotan 1 is the whole string with two beads changed. Melanotan 2 is the middle seven beads of melanotan 1, two of them changed again, cut out and fastened into a loop, and it acts on more of the body's melanocortin receptors5710. Change one more detail, swapping the amide at its tail for a plain acid, and you have bremelanotide, also known as PT-14151321.
The 26-fold potency figure comes from mouse melanoma cells, and the other early tests used frog skin, not people1.
What did the melanotan 1 trials measure?
The first human trial, in JAMA in 1991, gave 28 healthy white men 10 injections under the skin over 12 days, or saline. Everyone wore high-potency sunscreen throughout. Skin darkened in both poor tanners and good tanners on the drug and not at all on placebo, and the tan peaked 1 to 3 weeks after the last injection2.
A pharmacokinetic study in three men found that an injection under the skin was completely absorbed, while the same peptide swallowed left no detectable drug in the blood. Its half-life was 0.8 to 1.7 hours, and the tan was still visible 3 weeks after the course ended3.
In 2004, three more trials paired it with light. Three of four people on melanotan 1 tanned and had 47% fewer sunburn cells after a measured dose of UV-B. With real sunlight, the drug group tanned more and kept it at least 3 weeks longer, and people on sun alone needed 50% more time in the sun for the same tan4.
The trials dosed by body weight, 0.08 to 0.21 mg per kg a day, in courses that ran from 10 days to 4 weeks34. Those numbers describe the research, not a protocol to copy.
Why is Scenesse approved for EPP?
Erythropoietic protoporphyria, or EPP, is a severe light sensitivity: in sunlight, patients have excruciating pain9. Two randomized, placebo-controlled trials in the New England Journal of Medicine tested a 16 mg afamelanotide implant every 60 days. In the US trial, patients on the implant spent a median 69.4 hours in direct sunlight without pain over 6 months, against 40.8 hours on placebo. In the European trial, they had fewer phototoxic reactions, 77 against 1469.
The European Commission authorized Scenesse on December 22, 2014, under exceptional circumstances12, and the FDA approved it on October 8, 201911. The US label covers adults with a history of phototoxic reactions from EPP, one implant above the hip every 2 months, placed by a trained healthcare professional10. That implant is the only approved form of melanotan 1. Powders sold online as melanotan 1 and 2 come from outside any regulated supply, with open questions about how they are made and dosed15.
What did the melanotan 2 trials measure?
Its one tanning study, in 1996, was a pilot in three men. Two of them had darker skin on the face, upper body and buttock a week after a course of only five low doses5. It also showed the side of the drug that would set its course: a stretching and yawning spell that came with spontaneous erections for 1 to 5 hours after dosing5.
The Arizona group followed that thread. In a 1998 placebo-controlled crossover trial, 8 of 10 men with psychogenic erectile dysfunction had clear erections on melanotan 2, with an average 38 minutes of firm rigidity against 3 minutes on placebo6. Across 20 men in their studies, 17 had erections without any sexual stimulation, and sexual desire rose after 68% of doses against 19% of placebo doses7.
That pointed to the brain, and the researchers called for more study of centrally acting drugs on sexual desire22. The drug that reached approval was its descendant: bremelanotide, approved by the FDA in 2019 as Vyleesi, for acquired, generalized low sexual desire (HSDD) in premenopausal women13. We found no approval of melanotan 2 for any use in Drugs@FDA (November 2026), and the FDA lists it among bulk substances for compounding that may present significant safety risks14.
What side effects do the melanotans cause?
In the tanning trials, melanotan 1's side effects were minor: nausea and brief facial flushing34. In the EPP trials behind the label, the common ones were implant-site reactions (21% against 10% on placebo), nausea (19% against 14%) and fatigue (6% against 3%)10. Serious allergic reactions, including anaphylaxis, have been reported since approval10.
Melanotan 2 brings more. Nausea, stretching and yawning, and less appetite were all more frequent than on placebo in the 1998 trial, and none needed treatment6. At the trial dose, 12.9% of men had severe nausea7. Beyond trials, the FDA notes published case reports of melanoma, a brain-swelling syndrome called PRES, an overstimulated nervous system and priapism in people using it14.
Commonly reported: with melanotan 2, nausea and facial flushing after the first doses that ease with time, a fast and deep tan, darker freckles, frequent yawning, spontaneous erections and a smaller appetite; with melanotan 1, a slower, more even tan with milder nausea and few of melanotan 2's other effects.
Those reports match the trials, where melanotan 2's nausea, yawning and loss of appetite were transient6, and its spontaneous erections came and went for 1 to 5 hours after a dose5.
Does melanotan change moles?
Yes. Both darken pigmented skin, moles and freckles included. The Scenesse label warns of darker existing moles and freckles, lists moles (melanocytic nevus) as a side effect in 4% of patients against 2% on placebo, and recommends a full-body skin exam twice a year10.
With unregulated melanotan, published reports describe moles that changed after an unlicensed "sun tan jab"16, crops of new moles in a man with a history of melanoma who gave himself a synthetic α-MSH, which lightened after he stopped17, and new moles and darker existing ones within 24 hours of a single melanotan 2 injection18. One report describes a 20-year-old woman who used sunbeds and a 3- to 4-week melanotan 2 course and was diagnosed with melanoma three months later19. A 2017 review counted four case reports of melanoma arising in existing moles during or shortly after melanotan use, and concluded that conclusive evidence linking the two is lacking15.
New moles, or a mole that changes in size, shape or color, are a reason to see a dermatologist.
Which peptides darken skin?
Of the peptides people ask about, three do it by design or as a side effect. Melanotan 1 has the human tanning trials, with sunscreen on and with sun24. Melanotan 2 darkened skin in its one small pilot5. Bremelanotide, built for sexual desire, causes patches of darker skin in about 1% of women at up to 8 doses a month, more often with daily dosing13.
None of them replaces sun protection. The Scenesse label tells patients to keep up their sun and light protection while on the implant10, and in the 2004 trials the drug worked together with sunlight to deepen the tan4.
What comes next for afamelanotide?
Its maker is testing it beyond EPP. A phase 3 trial planned for 200 people with vitiligo compares Scenesse plus narrow-band UV-B light against the light alone; the registry, last updated in July 2025, lists it as active and no longer recruiting20. If it succeeds, the tanning molecule from 1980 will have found a second use in medicine, still by the same route: more pigment where the skin needs it.
Sources
- Sawyer TK et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980. PubMed 6777774
- Levine N et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991. PubMed 1658407
- Ugwu SO et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997. PubMed 9113347
- Dorr RT et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004. PubMed 15262693
- Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. PubMed 8637402
- Wessells H et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998. PubMed 9679884
- Wessells H et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000. PubMed 11035391
- Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006. PubMed 16412534
- Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015. PubMed 26132941
- SCENESSE (afamelanotide) implant, prescribing information. Clinuvel. DailyMed, revised May 2026. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Drugs@FDA: NDA 210797, SCENESSE, original approval October 8, 2019. accessdata.fda.gov
- European Medicines Agency. Scenesse (afamelanotide): EPAR, marketing authorisation December 22, 2014. ema.europa.eu
- VYLEESI (bremelanotide) injection, prescribing information. Cosette Pharmaceuticals. DailyMed. dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of April 22, 2026). fda.gov
- Habbema L et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017. PubMed 28266027
- Langan EA et al. Change in moles linked to use of unlicensed "sun tan jab". BMJ. 2009. PubMed 19174439
- Cardones AR, Grichnik JM. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009. PubMed 19380666
- Schulze F et al. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. 2014. PubMed 24334249
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014. PubMed 24355990
- ClinicalTrials.gov NCT06109649. A study to compare the efficacy and safety of SCENESSE and narrow-band ultraviolet (NB-UVB) light versus NB-UVB light alone in patients with vitiligo. Clinuvel. clinicaltrials.gov
- Diamond LE et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006. PubMed 16839319
- Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology. 2000. PubMed 11018622
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.